logo

Asia-Pacific Autoimmune Disease Diagnostics Market Size (2024 - 2029)

The Asia-Pacific autoimmune disease diagnostics market is projected to experience growth over the forecast period, driven by the need for accurate and timely diagnosis of autoimmune diseases. The collaboration between physicians and clinical laboratories is enhancing the efficiency of diagnostics, as physicians can direct patients to laboratories equipped for immunoassays, ensuring seamless communication of test results. The integration of Electronic Medical Records (EMR) and access to real-time data further streamline the diagnostic process, contributing to the expansion of the market.

Home Market Analysis Healthcare Research Medical Devices Research Diagnostic Devices Research Clinical Diagnostic Devices Research Clinical Diagnostic Laboratory Equipment Research Disease Specific Diagnostic Devices Research Immune System Diagnostics Research Asia-Pacific Autoimmune Disease Diagnostics Market Market Size

Market Size of Asia-Pacific Autoimmune Disease Diagnostics Industry

CAGR
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 1.24 Billion
Market Size (2029) USD 1.65 Billion
CAGR (2024 - 2029) 5.96 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

APAC Autoimmune Disease Diagnostics Market Analysis

The Asia-Pacific Autoimmune Disease Diagnostics Market size is estimated at USD 1.24 billion in 2024, and is expected to reach USD 1.65 billion by 2029, growing at a CAGR of 5.96% during the forecast period (2024-2029).

The treatment of autoimmune diseases requires diagnosis of the disease at the onset of disease or later. This involves clinical laboratories checking for symptoms and providing the information to physician for better treatment of the disease. All the diagnostic laboratories do not have proper equipment for carrying out immunoassays. In that case, patient will face trouble in getting the tests done and then handing over the result to the physician. To overcome these problems, recently physicians and clinical laboratories started collaborating. Since, a physician knows where proper immunoassays and immunodiagnostics can be carried out, physician collaborates with that laboratory and suggests patient to get their tests done from there and the results will directly be sent to the physician. Furthermore, with increasing usage of Electronic Medical Records (EMR), labs have access to real-time test data and metrics extracted from the Laboratory Information System (LIS) and physicians too have access to these records, which increases efficiency in diagnosis, thus boosting autoimmune diagnostics market.

APAC Autoimmune Disease Diagnostics Industry Segmentation

Autoimmunity involves the loss of normal immune homeostasis, as the organism produces an abnormal response to its own tissue. Autoimmune diseases generally involve the presence of self-reactive T cells, autoantibodies, and inflammation. 

By Disease Type
Systemic Autoimmune Disease
Rheumatoid Arthritis
Psoriasis
Systemic Lupus Erythematosus (SLE)
Multiple Sclerosis
Other Systemic Autoimmune Diseases
Localized Autoimmune Disease
Inflammatory Bowel Disease
Type 1 Diabetes
Thyroid
Other Localized Autoimmune Diseases
By Diagnosis
Regular Laboratory Tests
Inflammatory Markers
Immunologic Assays
Antibody Tests
Other Tests
Geography
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Need A Different Region Or Segment?
Customize Now

Asia-Pacific Autoimmune Disease Diagnostics Market Size Summary

The Asia-Pacific autoimmune disease diagnostics market is poised for significant growth, driven by the increasing need for accurate and timely diagnosis of autoimmune diseases. This market is characterized by the collaboration between physicians and clinical laboratories to enhance diagnostic efficiency. As not all diagnostic facilities are equipped with advanced immunoassay technologies, physicians play a crucial role in directing patients to appropriate laboratories, ensuring that test results are promptly communicated. The integration of Electronic Medical Records (EMR) and Laboratory Information Systems (LIS) has further streamlined this process, allowing for real-time access to test data, which in turn enhances the diagnostic capabilities. The market is segmented into various diagnostic categories, including regular laboratory tests, inflammatory markers, immunologic assays, and antibody tests, each contributing to the overall market dynamics.

The growth of the Asia-Pacific autoimmune disease diagnostics market is underpinned by several key factors, such as the cost-effectiveness of diagnostic procedures, advancements in biotechnology and pharmaceuticals, and the high sensitivity and specificity of immunoassays. These immunologic assays offer superior accuracy compared to traditional tests, facilitating precise disease detection and reducing the need for secondary verifications, which ultimately lowers costs. The market is dominated by major players like Abbott Laboratories, BioMerieux, and Thermo Fisher Scientific, who are heavily investing in research and development to drive innovation and expand their market presence. As these companies continue to focus on strategic growth initiatives, the market is expected to experience robust expansion over the forecast period.

Explore More

Asia-Pacific Autoimmune Disease Diagnostics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Public Awareness about Autoimmune Diseases

      2. 1.2.2 Partnerships with Physicians and Clinical Laboratories

      3. 1.2.3 Technological Advancements

    3. 1.3 Market Restraints

      1. 1.3.1 Slow Turnaround Time for Autoimmune Disease Diagnostic Test Results

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Disease Type

      1. 2.1.1 Systemic Autoimmune Disease

        1. 2.1.1.1 Rheumatoid Arthritis

        2. 2.1.1.2 Psoriasis

        3. 2.1.1.3 Systemic Lupus Erythematosus (SLE)

        4. 2.1.1.4 Multiple Sclerosis

        5. 2.1.1.5 Other Systemic Autoimmune Diseases

      2. 2.1.2 Localized Autoimmune Disease

        1. 2.1.2.1 Inflammatory Bowel Disease

        2. 2.1.2.2 Type 1 Diabetes

        3. 2.1.2.3 Thyroid

        4. 2.1.2.4 Other Localized Autoimmune Diseases

    2. 2.2 By Diagnosis

      1. 2.2.1 Regular Laboratory Tests

      2. 2.2.2 Inflammatory Markers

      3. 2.2.3 Immunologic Assays

      4. 2.2.4 Antibody Tests

      5. 2.2.5 Other Tests

    3. 2.3 Geography

      1. 2.3.1 Asia-Pacific

        1. 2.3.1.1 China

        2. 2.3.1.2 Japan

        3. 2.3.1.3 India

        4. 2.3.1.4 Australia

        5. 2.3.1.5 South Korea

        6. 2.3.1.6 Rest of Asia-Pacific

Asia-Pacific Autoimmune Disease Diagnostics Market Size FAQs

The Asia-Pacific Autoimmune Disease Diagnostics Market size is expected to reach USD 1.24 billion in 2024 and grow at a CAGR of 5.96% to reach USD 1.65 billion by 2029.

In 2024, the Asia-Pacific Autoimmune Disease Diagnostics Market size is expected to reach USD 1.24 billion.

Asia-Pacific Autoimmune Disease Diagnostics Report Snapshots

Asia-Pacific Autoimmune Disease Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)